Literature DB >> 31691010

Trihexyphenidyl for treatment of dystonia in ataxia telangiectasia: a case report.

Liping Zhang1, Yu Jia2, Xiaohong Qi1, Mingyu Li2, Shiyu Wang1, Yuping Wang3.   

Abstract

Ataxia telangiectasia (AT) is an autosomal recessive multisystem disorder caused by mutations of ATM gene. And dystonia may develop as a late manifestation in typical AT. Here we report a novel homozygous frameshift ATM mutation (c.1402_1403delAA; p. K468Efs*18) in a 10-year-old male. The patient was diagnosed as typical AT according to clinical presentations which included progressive cerebellar ataxia, oculocutaneous telangiectasia, immune deficiency, and cerebellar atrophy. The genetic finding confirmed the diagnosis. Severe dystonia was presented in late stage of this disease. After 3 months of trihexyphenidyl treatment, the frequency of dystonia was reduced significantly. Although dystonia is not uncommon in phenotype spectrum of AT, compared with other symptoms of this syndrome, such as cerebellar ataxia and dysarthria, dystonia can be treated.

Entities:  

Keywords:  Ataxia telangiectasia; Dystonia; Trihexyphenidyl

Mesh:

Substances:

Year:  2019        PMID: 31691010     DOI: 10.1007/s00381-019-04399-3

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  8 in total

1.  Neuropathology in classical and variant ataxia-telangiectasia.

Authors:  Mijke M M Verhagen; Jean-Jacques Martin; Marcel van Deuren; Chantal Ceuterick-de Groote; Corry M R Weemaes; Berry H P H Kremer; Malcolm A R Taylor; Michèl A A P Willemsen; Martin Lammens
Journal:  Neuropathology       Date:  2011-10-24       Impact factor: 1.906

2.  Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites.

Authors:  R Saunders-Pullman; D Raymond; A J Stoessl; D Hobson; K Nakamura; T Nakamura; S Pullman; D Lefton; M S Okun; R Uitti; R Sachdev; K Stanley; M San Luciano; J Hagenah; R Gatti; L J Ozelius; S B Bressman
Journal:  Neurology       Date:  2012-02-15       Impact factor: 9.910

3.  Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate.

Authors:  Andreea Nissenkorn; Sharon Hassin-Baer; Sheera F Lerman; Yonit Banet Levi; Michal Tzadok; Bruria Ben-Zeev
Journal:  J Child Neurol       Date:  2012-05-01       Impact factor: 1.987

Review 4.  Ataxia-telangiectasia: diagnosis and treatment.

Authors:  Susan Perlman; Sara Becker-Catania; Richard A Gatti
Journal:  Semin Pediatr Neurol       Date:  2003-09       Impact factor: 1.636

5.  Brain glucose metabolism in adults with ataxia-telangiectasia and their asymptomatic relatives.

Authors:  Nora D Volkow; Dardo Tomasi; Gene-Jack Wang; Yana Studentsova; Brad Margus; Thomas O Crawford
Journal:  Brain       Date:  2014-04-17       Impact factor: 13.501

6.  Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals.

Authors:  C G Woods; A M Taylor
Journal:  Q J Med       Date:  1992-02

Review 7.  More than ataxia - Movement disorders in ataxia-telangiectasia.

Authors:  Hélio Afonso Ghizoni Teive; Carlos Henrique Ferreira Camargo; Renato Puppi Munhoz
Journal:  Parkinsonism Relat Disord       Date:  2017-12-12       Impact factor: 4.891

Review 8.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

  8 in total
  1 in total

1.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.